Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New phase II trial studies REGN-4461 for generalized lipodystrophy

Jan. 30, 2020

FDA approves Monoferric injection for the treatment of iron deficiency anemia

Jan. 30, 2020

Phase II study of AKCEA-ANGPTL3-LRx meets primary endpoint of significant triglyceride lowering

Jan. 29, 2020

Melanocortin MC2 receptor antagonists disclosed by Crinetics Pharmaceuticals

Jan. 29, 2020

Mutant TP53 affects fat metabolism

Jan. 29, 2020

FDA approves Trijardy XR for type 2 diabetes

Jan. 28, 2020

Genetic removal of mast cell Tph1 protects mice from developing obesity and insulin resistance

Jan. 28, 2020

Metrion Biosciences describes new KCNA3 channel blockers

Jan. 24, 2020

Janssen Pharmaceutica NV patents prostanoid EP3 receptor antagonists

Jan. 24, 2020

Thyradin S.I.V. Injection approved in Japan for myxedema coma and hypothyroidism

Jan. 24, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...